To our knowledge, this is the first network meta-analysis (NMA) to comprehensively evaluate gynecologic tumor risk from GLP-1 receptor agonists and SGLT2 inhibitors, stratified by both agent and dosage, with exclusive focus on female participants. The gene discussed is GLP1R; the disease is female reproductive system neoplasm.